Neuroprotection in post-stroke epilepsy: A realistic goal?  by Belcastro, Vincenzo
Seizure 20 (2011) 665Letter to the Editor
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizNeuroprotection in post-stroke epilepsy: A realistic goal?
I read with great interest the study by van Tuijl et al. aimed to
investigate the anti-epileptogenic effect of levetiracetam in stroke
patients in order to prevent poststroke seizures and epilepsy.1
However, due to several problems encountered during execution
of this trial, the authors concluded that this trial seems not
feasible.1
On the basis of the similarity of the cascade of synaptic and
intracellular events exhibited by epilepsy and brain ischemia,
antiepileptic drugs (AEDs) have been tested as possible neuro-
protective agents in animal models of stroke.2 Among the AEDs,
levetiracetam may have a crucial role in the regulation of
epileptogenesis and neuroprotection and some particular mechan-
isms of action of levetiracetam might be involved in neuroprotec-
tion after brain ischemia.3
There are different pathophysiological processes underlying
early and late seizures after stroke, with a predominance of acute
cellular biochemical disturbances in early seizures and epilepto-
genic gliotic scarring in late seizures.4
Interestingly, literature data support the view that patients
with epilepsy exhibit an increased risk for stroke5 but the effect of
late onset poststroke seizures on recurrent brain ischemia has not
been investigated.
Experimental observations have demonstrated that levetirace-
tam has a direct ability to protect against the neurotoxicity induced
by several chemical compounds3 and levetiracetam’s neuropro-
tective properties have been investigated in the rat middle cerebral
artery occlusion model (i.e. a condition of focal cerebral ischemia).3
Although the need for clinical studies to investigate the beneﬁts
of prophylactic treatment to prevent poststroke epilepsy is clear,
the study by van Tuijl et al. concluded that the problems
encountered during this prophylactic trial seem unavoidable.1
For these reasons, the conclusions of the work by van Tuijl et al.
could suggest the need for a different clinical study aimed no to1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.04.012investigate the anti-epileptogenic effect of levetiracetam in stroke
patients but a study aimed at investigating the possible
neuroprotective effect of levetiracetam in brain ischemia in a
clinical setting. Thus, a multicentre, prospective study could be
designed with the goal to assess the possible neuroprotective role
of levetiracetam in order to prevent the recurrence of brain
ischemia after ﬁrst stroke in patients on levetiracetam medication
for poststroke epilepsy.
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